GO Term | Evidence Code | PMID |
---|---|---|
complement receptor mediated signaling pathway | ||
positive regulation of developmental growth | ||
positive regulation of type IIa hypersensitivity | ||
fatty acid metabolic process | ||
inflammatory response |
GO Term | Evidence Code | PMID |
---|---|---|
protein-containing complex | ||
extracellular space | ||
extracellular region | ||
cell surface |
GO Term | Evidence Code | PMID |
---|---|---|
endopeptidase inhibitor activity | ||
protein binding | ||
C5L2 anaphylatoxin chemotactic receptor binding | ||
lipid binding | ||
receptor ligand activity |
Location | References |
---|---|
DO ID | Disease Name | Source |
---|---|---|
DOID:0060284 | paroxysmal nocturnal hemoglobinuria | |
DOID:0080162 | lupus nephritis | |
DOID:0080301 | atypical hemolytic-uremic syndrome | |
DOID:0080600 | COVID-19 | |
DOID:0080750 | erythema nodosum | |
DOID:0110019 | age related macular degeneration 7 | |
DOID:0110021 | age related macular degeneration 9 | |
DOID:0110861 | autosomal recessive polycystic kidney disease | |
DOID:10325 | silicosis | |
DOID:10591 | pre-eclampsia |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.1.1
Last updated: February 17, 2025